- Home
- DYAI vs PTN Comparison
DYAI vs PTN Comparison
Compare DYAI & PTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DYAI
- PTN
- Stock Information
- Founded
- DYAI 1979
- PTN 1986
- Country
- DYAI United States
- PTN United States
- Employees
- DYAI N/A
- PTN N/A
- Industry
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- PTN Biotechnology: Pharmaceutical Preparations
- Sector
- DYAI Health Care
- PTN Health Care
- Exchange
- DYAI Nasdaq
- PTN Nasdaq
- Market Cap
- DYAI 31.5M
- PTN 25.4M
- IPO Year
- DYAI 2004
- PTN 1993
- Fundamental
- Price
- DYAI $1.47
- PTN $0.78
- Analyst Decision
- DYAI Strong Buy
- PTN Strong Buy
- Analyst Count
- DYAI 1
- PTN 1
- Target Price
- DYAI $6.00
- PTN $17.00
- AVG Volume (30 Days)
- DYAI 91.0K
- PTN 365.1K
- Earning Date
- DYAI 11-12-2024
- PTN 02-13-2025
- Dividend Yield
- DYAI N/A
- PTN N/A
- EPS Growth
- DYAI N/A
- PTN N/A
- EPS
- DYAI N/A
- PTN N/A
- Revenue
- DYAI $3,364,548.00
- PTN $2,384,113.00
- Revenue This Year
- DYAI $51.30
- PTN N/A
- Revenue Next Year
- DYAI $73.26
- PTN N/A
- P/E Ratio
- DYAI N/A
- PTN N/A
- Revenue Growth
- DYAI 13.82
- PTN N/A
- 52 Week Low
- DYAI $0.93
- PTN $0.68
- 52 Week High
- DYAI $2.67
- PTN $5.65
- Technical
- Relative Strength Index (RSI)
- DYAI 44.84
- PTN 34.59
- Support Level
- DYAI $1.47
- PTN $0.82
- Resistance Level
- DYAI $1.70
- PTN $0.99
- Average True Range (ATR)
- DYAI 0.16
- PTN 0.11
- MACD
- DYAI -0.05
- PTN -0.02
- Stochastic Oscillator
- DYAI 3.70
- PTN 16.64
About DYAI Dyadic International Inc.
Dyadic International Inc is a world-wide biotechnology platform company. The company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
About PTN Palatin Technologies Inc.
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.